Quantitative analyses integrating all blotting data testing five samples per tumor (n = 5) confirmed that AMPKα1 phosphorylation, p-S6 inhibition, p-Akt inhibition and LC3B-II conversion were significant in tumor tissues with ASP4132 administration (Fig. 6E–H, lower panels). The gene discussed is MAP1LC3B; the disease is neoplasm.